Abha Gyani
Internal Medicine · San Antonio, TXNPI 1114960465
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by AbbVie at 48.4% of the total. Reporting peaked in 2021 at $829 and has fallen 83.8% since, to $135 in 2025.
Across 39 payments — averaging $46.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$884
- Galderma Laboratories, L.p.$642
- Revance Therapeutics, Inc.$204
- Lumenis, Inc$57
- Kerecis Limited$39
Across 31 payments — averaging $17,581 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$488K
- Sanofi US Services Inc.$36K
- Chiesi USA, Inc.$15K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- Lucid Diagnostics Inc.$500
What the payments were for
- Food & beverage$1,826100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 23 | $884 |
| Galderma Laboratories, L.p. | 9 | $642 |
| Revance Therapeutics, Inc. | 4 | $204 |
| Lumenis, Inc | 2 | $57 |
| Kerecis Limited | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAXI$146
How this compares
$1,826 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium | 12 | $313 |
| AmantadineAmantadine Hcl | 12 | $229 |
| Metoprolol Succinate | 19 | $100 |
| Levothyroxine Sodium | 16 | $75 |
| Clonidine Hcl | 14 | $39 |
| Alendronate Sodium | 15 | $32 |
| Omeprazole | 11 | $24 |
| Amlodipine Besylate | 11 | $14 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Antonio
- Manuel RodriguezSan Antonio$263K
- Matthew CatesSan Antonio$248K
- Fabian Rodas OchoaSan Antonio$68K
- Darius BuzenasSan Antonio$49K
- Spencer BerthelsenSugar Land$891K
- Hameed AliTemple$773K
- Marc TribbleDallas$693K
- Gary SinclairDallas$599K
- Mohammed Al-NajjarEl Paso$586K
- Han SchmidlyDallas$465K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.